BTIG Initiates Buy on Zevra After $50M Portfolio Sale and Debt-Free Move

BTIG starts coverage on ZVRA with Buy rating and $23 target after Zevra sells SDX portfolio for $50 million and becomes debt-free.

BTIG Initiates Buy on Zevra After $50M Portfolio Sale and Debt-Free Move
Credit: Zevra Therapeutics
Already have an account? Sign in.